“In the following 10 to 20 years, the next R&D peak in small molecules lies in protein degradation; protein degraders will have a market worth at least $100bn,” Liqiang Fu, co-founder and chief technology officer of GluBio Therapeutics, predicted at the recent BioPharma Innovation Week in Shanghai.
Proteolysis targeting chimera (PROTAC) and molecular glues (MGs) are the two main types of protein degrader approaches and globally, in terms of clinical trial progress, multiple PROTACs have
Key Takeaways
- Oncology is the dominant therapeutic area for protein degraders in both China and globally.
- Of the 26 drugs developed by Chinese firms that are already in trials, two estrogen receptor-targeted degraders are in Phase III for breast cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
